• Perioperative thrombosis is a major cause of morbidity and mortality in congenital heart disease.
• Neonates and infants undergoing repair of congenital heart lesions were prospectively followed.
• Elevated von Willebrand factor (VWF) to ADAMTS-13 activity ratios typified the postoperative period.
• Thrombosis was associated with preoperative VWF activity and cryoprecipitate transfusion Summary. Background: The surgical repair of congenital heart malformations is frequently complicated by perioperative thrombosis of unclear etiology. An imbalance between von Willebrand factor (VWF) and ADAMTS-13 is an emerging variable in thrombosis. Objectives: To describe perioperative changes to VWF, ADAMTS-13 and NETosis, and evaluate clinical and biochemical associations with postoperative thrombosis. Methods: Neonates and infants undergoing palliation or definitive surgical repair of congenital heart malformations were recruited (n = 133). Preoperative and postoperative plasma levels of VWF, ADAMTS-13 and markers of NETosis were determined. Patients were followed for up to 30 days for the occurrence of thrombosis. Univariate and multivariate logistic regression analyses were conducted to identify variables associated with thrombosis. Results: We identified significant postoperative increases in VWF activity, VWF level, DNA-histone complexes and cell-free DNA with an overall decrease in ADAMTS-13 activity. Patients experiencing postoperative thrombotic events (9%) were characterized by surgery performed at a lower intraoperative temperature, higher preoperative lactic acid levels, and higher preoperative VWF activity and level. A multivariate logistic regression model identified preoperative VWF activity (odds ratio (OR) 8.39 per IU mL
À1
, 95% confidence interval [CI] 1.73-40.55) and transfusion of cryoprecipitate (OR 1.10 per mL kg
Introduction
Neonates and infants with congenital heart disease (CHD) undergo high-risk cardiac surgery, which can necessitate deep hypothermia circulatory arrest and warm reperfusion of ischemic tissues. This population is at high risk for postoperative thrombosis, an outcome that can be associated with significant morbidity or mortality. Although hemostatic abnormalities, coagulopathies and thrombosis are common perioperative challenges in cardiac surgery, pediatric patients undergoing repair of congenital heart malformations have unique risks, including irregular levels of coagulation factors [1] [2] [3] , platelet abnormalities [4] , and defects of fibrinolysis [5] . The use of intraoperative extracorporeal circulation can also generate vascular injury, coagulation defects, and platelet dysfunction [6, 7] . The risk for thrombosis is non-uniform across the CHD population. For example, children with a single ventricle physiology are at a particularly high risk of thrombosis [8] . Despite increased awareness of causal mechanisms and specific recommendations for thromboprophylaxis [9] , thrombosis continues to impact on the management of CHD.
Von Willebrand factor (VWF) is a large, multimeric glycoprotein that mediates platelet-platelet and plateletsubendothelium adhesion. Upon its release from activated platelets and the endothelium, VWF predominantly exists in the form of large, hyper-reactive multimers. The biological activity of VWF is primarily regulated by ADAMTS-13, a plasma metalloprotease that specifically degrades VWF into smaller, less thrombotic forms [10] [11] [12] [13] . Severe deficiency of ADAMTS-13 (typically activity levels < 10% of those in normal plasma) allows for the accumulation of ultralarge VWF and the deposition of platelet-rich thrombi in the microcirculation, manifesting clinically as thrombotic thrombocytopenic purpura [14] . Both ADAMTS-13 and VWF have been linked to arterial thrombosis (reviewed in [15] ). In a prospective study of nearly 6000 adults, individuals within the lowest quartile of ADAMTS-13 activity were shown to have a significantly elevated risk of ischemic stroke [16] . A pediatric case-control study similarly found a greater proportion of arterial ischemic stroke patients with ADAMTS-13 levels below the 10th percentile [17] . Elevated VWF has also been associated with ischemic stroke [18] . An imbalance between plasma levels of VWF and ADAMTS-13 has been described in a growing list of clinical conditions, including myocardial infarction [19] , inflammation and sepsis [20, 21] , pregnancy [22] , connective tissue disease [23] , organ transplantion [24] , and cardiac surgery in adults [25] . Postoperative changes to ADAMTS-13 and VWF have been previously evaluated in patients with cyanotic CHD. Increased levels of VWF were accompanied by modest increases in ADAMTS-13 activity [26] . However, associations with postoperative thrombosis were not evaluated.
Neutrophil extracellular traps (NETs) are large weblike complexes of DNA, histones, granule proteins and proteases that are generated through neutrophil activation by a cell death mechanism termed 'NETosis' [27] . NETs were first recognized for their ability to physically trap and kill pathogens [28] , but it was later discovered that NETs in the circulation provide a physical scaffold for coagulation [29] , cause endothelial toxicity [30, 31] , and are thrombogenic in animal models of venous and arterial thrombosis [32, 33] . In humans, NET burden correlates with the occurrence of deep vein thrombosis and disease severity in thrombotic microangiopathies [34, 35] . It was recently shown that NETs interact with VWF under shear force [36] and can stimulate endothelial VWF release [37] . Whereas neutrophils isolated from healthy neonates show a capacity for NET generation [38] , perioperative NETosis and associations with thrombosis have not been evaluated in pediatric populations.
For these reasons, we aimed to characterize VWF, ADAMTS-13 and markers of NETosis in a population at high risk of perioperative thrombosis. We describe trends in these variables relative to common features of pediatric cardiac surgery, and examine how they relate to the occurrence of postoperative thrombosis.
Materials and methods

Study population
With Institutional Review Board approval, we recruited and prospectively followed a total of 133 neonates and infants undergoing palliation or repair of congenital heart malformations at Boston Children's Hospital. Informed consent was obtained from either parents or legal guardians. Patients were recruited over a period of 17 months from April 2015 to September 2016. All patients presenting for surgery were screened for eligibility/exclusion criteria regardless of their gender, race, or socioeconomic status. Translated versions of the informed consent form and certified interpreters were used for screening and recruitment of non-English-speaking subjects. Exclusion criteria included the presence of documented hematologic, oncologic, renal or liver disease, and preoperative transfusion of plasma-containing blood products. Patients were identified preoperatively, screened for inclusion/exclusion criteria, and followed for a period of 30 days after surgery or until discharge for the occurrence of thrombotic complications. Thrombotic events were identified by the presence of clinical symptoms requiring additional diagnostic testing and specific treatments. Given a known prevalence of thrombotic events in neonates of 20-25% [39] , a minimum of 60 patients were deemed to be necessary to achieve 80% power. We projected that 12-15 patients would experience thrombotic events across a study period of 30 postoperative days. We estimated that the activity and concentration indexes of ADAMTS-13/ VWF in patients experiencing thrombotic events would be wider (50% AE 20%), being represented by (i) proportionally low ADAMTS-13 and/or (ii) proportionally high VWF, in contrast to narrow (20% AE 10%) indexes in the group of patients free of thrombotic complications. This provides a 40% effect size between thrombosis and nonthrombosis groups.
Sample collection
Whole blood samples were collected in 1.8-mL sodium citrated tubes preoperatively in the operating room under general anesthesia after venous and arterial access had been obtained but before blood or product transfusion. A second sample was collected 24 h after surgery. Plasma generated from each sample was aliquoted and stored at À 80°C for future analysis.
Cardiopulmonary bypass (CPB) and transfusion protocols Anesthesia and CPB management for all patients was standardized according to established departmental protocols. Priming of the CPB circuit was calculated on the basis of the patient's estimated blood volume and total circuit volume to maintain a hematocrit of > 30%. A 1 : 1 mixture of packed red blood cells (RBCs) and fresh frozen plasma was used to prime the CBP circuit and maintain an adequate intravascular volume during surgery. Upon separation from the CPB circuit, non-surgical bleeding was treated with single or repeated platelet transfusions (5 mL kg À1 per transfusion). If bleeding persisted, 5 mL kg À1 cryoprecipitate was transfused.
Recombinant activated factor VII (FVIIa) was administered at the discretion of the care team. Hematocrit was maintained at ≥ 40% in neonates with postoperative cyanosis and at ≥ 35% in non-cyanotic patients. Intraoperative anticoagulation was initiated and maintained with unfractionated heparin to achieve an activated clotting time of > 480 s.
Determination of VWF concentration and collagen-binding activity
The VWF antigen concentration was determined by ELISA according to the manufacturer's instructions (Abcam, Cambridge, MA, USA). VWF activity was quantified by determining its binding to type III collagen by use of a commercially available VWF:CBA ELISA performed according to the manufacturer's instructions (Technoclone, Vienna, Austria). Citrated plasma samples were assayed in duplicate.
Quantification of ADAMTS-13 activity
The fluorogenic peptide substrate FRETS VWF73 (Peptides International, Louisville, KY, USA) was used to determine ADAMTS-13 activity, as previously described [40] . Fluorescence readings were taken at 60-s intervals for 60 min at 30°C with a Victor X3 plate reader (PerkinElmer, Waltham, MA, USA). Initial reaction rates were calculated as the change in fluorescence reading at 430 nm per minute. ADAMTS-13 activity was presented relative to a dilution series of pooled adult normal plasma. Samples were assayed in duplicate.
Detection of DNA-histone complexes in plasma DNA-histone complexes in plasma were measured with a commercially available cell death ELISA, according to the manufacturer's instructions (Roche, Basel, Switzerland). Citrated plasma samples were diluted 1 : 4 in incubation buffer and assayed in duplicate. Sample concentration was determined relative to a dilution series of purified DNA-histone material provided with the kit. Results were presented relative to levels of DNA-histone complexes found in control plasma.
Quantification of cell-free DNA
This method was performed according to Diaz et al. [34] . Citrated plasma (10 lL) was diluted 1 : 10 with phosphate-buffered saline (PBS) and mixed (1 : 1; v/v) with 2 lM SyTox Green (Thermo, Waltham, MA, USA). Known concentrations of circular pcDNA3.1 plasmid DNA were used to create a standard curve. SyTox Green fluorescence was linear across four log folds of DNA concentration in our standard curve. Background fluorescence was determined with 1 lM SyTox Green in 1 9 PBS.
Multimeric analysis of VWF
Plasma samples were electrophoresed on a 0.7% SDSagarose gel, and transferred overnight in a trans-blot cell tank (Bio-Rad, Hercules, CA, USA) onto Immobilon-P poly(vinylidene difluoride) membranes (Millipore, Billerica, MA, USA). Membranes were blocked in clear milk (Pierce), and incubated for 2 h with a polyclonal rabbit anti-human VWF antibody (Abcam) at a 1 : 20 000 dilution in 0. 
Results
Study population
One hundred and thirty-three neonates and infants (353 patients screened, 196 deemed to be eligible, 140 enrolled, and seven with incomplete data) were consented to participate in this study. General demographics, conditions of CPB and transfusion volumes are summarized in Table 1 . Basic preoperative and postoperative laboratory results, including hematocrit, platelet count, and coagulation tests, are summarized in Table 2 . A combination of single-ventricle palliation (21%) and two-ventricle repairs (79%) was included in the study. A majority of patients (80%) received postoperative transfusion of blood products as follows: exclusively platelets (plasma-reduced and nonplasma-reduced) (24.8%); a combination of platelets and cryoprecipitate (46%); or platelets, cryoprecipitate, and recombinant FVIIa (7.5%). Twenty per cent (27/133) of patients did not receive transfusion of blood products, with the exception of the CPB prime volume. Significant perioperative thrombotic events occurred in 9% of patients, and were identified by the presence of clinical symptoms requiring additional diagnostic testing and specific treatments.
VWF activity and concentration increase significantly postoperatively
To ensure that our analysis included patients with congenital heart malformations representative of this age group undergoing varied surgical procedures, a subpopulation of 71 individuals were used for perioperative assessment of VWF, ADAMTS-13, and NETosis. Infants and neonates with the following congenital heart malformations were included: (i) single-ventricle defects (n = 20);
(ii) tetralogy of Fallot (n = 21); and (iii) two-ventricle circulations that included transposition of the great arteries, truncus arteriosus, and valvular repairs (n = 30). Using this cohort, we first characterized perioperative changes to plasma VWF. The VWF antigen level in plasma increased significantly from a mean preoperative level of 1.8 AE 1.5 IU mL À1 to 2.8 AE 1.5 IU mL À1 (P < 0.001).
This was accompanied by increased VWF collagen-binding activity, which increased from a preoperative baseline level of 1.1 AE 0.5 IU mL À1 to 2.1 AE 0.8 IU mL
À1
(P < 0.001) (Fig. 1) . Univariate linear regression analysis did not identify significant relationships between postoperative VWF activity and level with variables that are commonly associated with CPB (Table S1 ). In addition to quantifying VWF antigen concentration and activity, we evaluated the distribution of VWF multimers preoperatively and postoperatively. HMW VWF multimers released by platelets and endothelial cells are degraded to smaller forms under circulatory shear stress by ADAMTS-13. VWF multimers can be categorized as LMW (500-2500 kDa), IMW (3000-5000 kDa), and HMW (5500-10 000 kDa). Changes to the relative size distribution of multimers can suggest release, enhanced proteolysis or consumption of VWF. The VWF multimer profile for five patients experiencing postoperative thrombosis and five non-thrombosis patients is shown in Fig. 2 . For each sample, the sum densitometry in each molecular weight tercile was determined relative to the entire lane. This analysis revealed relative increases in IMW and HMW VWF multimers at 24 h following surgery (P = 0.017 and P = 0.007, respectively) accompanied by a lower relative abundance of LMW multimers (P = 0.005) (Fig. 2B) . Analysis of the entire lane densitometry demonstrated a higher overall VWF signal in the sample obtained 24 h after surgery (P < 0.001), consistent with measurements of total VWF level by ELISA.
Postoperative changes to ADAMTS-13 activity
We measured the preoperative and postoperative activity of ADAMTS-13 by using a fluorogenic VWF substrate (FRETS VWF73) under static conditions. Across the cohort, there was a small overall decrease in postoperative ADAMTS-13 activity (63% AE 31% versus 58% AE 23%, P = 0.025) (Fig. 1C) . Univariate linear regression of postoperative ADAMTS-13 activity demonstrated significant associations with body weight, bovine serum albumin, lowest body temperature, lactic acid levels, and transfusion of RBCs, cryoprecipitate, and platelets (Table S1) than neonates (Fig. 1D ), in line with previous descriptions of reduced ADAMTS-13 activity in healthy neonates [41] .
Markers of perioperative NETosis
Because cardiac surgery and CPB induce an inflammatory response, and NETs have been shown to interact with VWF [36] , we determined the NET burden in preoperative and postoperative plasma samples. At baseline, plasma DNA-histone complex levels across this cohort were determined to be 2.5 AE 1.6-fold greater than those in control plasma, with levels increasing to 4.2 AE 3.5-fold postoperatively (P < 0.001) (Fig. 1E) . Univariate linear regression analysis of postoperative DNA-histone complex levels demonstrated significant associations with postoperative lactic acid levels (P = 0.005), volume of RBC transfusion (P = 0.013), and volume of platelet transfusion (P = 0.012) (Table S1 ). Similarly, the plasma cell-free DNA level increased significantly from a mean preoperative level of 2.7 AE 2.2 ng mL À1 to 4.89 AE 4 ng mL À1 at 24 h after surgery (Fig. 1F) . Univariate regression analysis of postoperative cell-free DNA demonstrated a significant association with postoperative lactic acid levels (P = 0.005) (Table S1 ).
Preoperative plasma VWF activity is associated with postoperative thrombotic events Clinically significant thrombotic events occurred at a rate of 9% (12/133) across the cohort. The clinical characteristics of this group are summarized in Table 3 . Of the 12 patients who developed thrombotic events, eight underwent major aortic reconstruction surgery, and seven underwent palliation of single-ventricle physiology. Analysis of ADAMTS-13, VWF and NETosis revealed that patients experiencing thrombosis had higher P r e P r e P r e P r e P r e P r e P r e P r e P r e P r e postoperative lactic acid levels, preoperative VWF activity and VWF antigen level in addition to receiving larger transfusion volumes of RBCs, cryoprecipitate, and platelets (Table 4) . As surrogates of postoperative bleeding, we measured chest tube output over 24 h postoperatively and chest closure times intraoperatively. This demonstrated that patients experiencing thrombosis had greater chest tube drainage per kg À1 24 h À1 and prolonged sternal closure after completion of the surgical procedure (Table 4) . Recombinant FVIIa was used at a similar frequency among thrombosis and non-thrombosis patients. Univariate logistic regression analysis identified CPB time, lowest body temperature, circulatory arrest, lactic acid level, preoperative VWF activity and level, RBC and cryoprecipitate transfusion and single-ventricle physiology to be significantly associated with thrombosis (Table 5) .
By multivariate logistic regression analysis, preoperative VWF activity (OR 8.39, 95% CI 1.73-40.55, P = 0.005) and cryoprecipitate transfusion (OR 1.10, 95% CI 1.03-1.17, P = 0.003) were significantly associated with postoperative thrombosis (Table 5) . A separate multivariate analysis with preoperative VWF activity categorized into tertiles revealed a stepwise increase in ORs with increasing VWF activity (ORs per tertile: first, reference; second, 7.34, 95% CI 0.68-79.77; and third, 16.23, 95% CI 1.79-147.59).
Discussion
Perioperative thrombosis continues to be a significant complication of cardiac surgery in neonates and infants. Despite advances in the field, the prevalence and severity © 2017 International Society on Thrombosis and Haemostasis of these complications have not appreciably changed over the last few years, owing to a lack of novel strategies that could modify postoperative thromboprophylaxis. Given the recent discovery of ADAMTS-13 as a risk factor for ischemic stroke in adult [16] and pediatric [17] populations, this study sought to investigate its potential role in perioperative thrombotic events in a diverse cohort of neonates and infants undergoing cardiac surgery with CPB.
In our cohort, an overall trend for attenuated ADAMTS-13 activity after cardiac surgery was found. However, changes to ADAMTS-13 were non-uniform. In approximately 50% of the patients tested, ADAMTS-13 activity was modestly increased from preoperative levels. ADAMTS-13 activity increased more commonly in neonates than infants, and this may be related to transfusion of plasma-containing blood products. Although some patients showed preoperative ADAMTS-13 activity levels lower than have been reported for healthy newborns [41] , no patients showed clinical signs of severe ADAMTS-13 deficiency. Moreover, the level of preoperative or postoperative ADAMTS-13 activity was not associated with thrombosis in this cohort.
Across the entire cohort, both VWF concentration and VWF activity were significantly elevated at 24 h following surgery. A careful analysis of the preoperative and postoperative VWF multimer distribution suggested that there was increased degradation of VWF at baseline, as reflected by an abundance of VWF LMW multimers prior to surgery. This may result from vascular injury or abnormal blood flow, which is often present in patients with CHD. An increase in the relative amount of VWF HMW multimers -the fraction of VWF with the greatest biological activity [42] -following surgery is consistent with acute perioperative release of VWF. The lack of association between cryoprecipitate transfusion and postoperative VWF additionally supports the acute release of VWF from endogenous sources such as endothelial Weibel-Palade bodies and platelet a-granules during and/ or immediately after surgery. Prior descriptions of adults undergoing cardiac surgery have attributed endogenous VWF release to the use of CPB [43] and surgical trauma [44] . Postoperative measurements of VWF were not associated with thrombosis after adjustment for covariates related to surgery and CPB. Howver, the level of preoperative VWF activity was indeed positively associated with perioperative thrombosis. Plasma levels of VWF are determined by both genetic and non-genetic influences. ABO blood group has a well-described influence on VWF half-life in the circulation [45] . However, this effect is not apparent until adolescence [46] , making physiologic variables potentially strong determinants of VWF levels in neonates and infants with CHD. Although VWF is intrinsically prothrombotic, elevated levels of VWF can also reflect a state of endothelial activation and injury [47, 48] . Both of these factors may underlie the apparent risk for pathologic thrombosis conferred by elevated preoperative VWF activity.
Plasma markers of NETosis, including DNA-histone complexes and cell-free DNA, were readily detected in all patient plasma samples, and showed increased levels in the postoperative period. Postoperative NET levels were associated with postoperative lactic acid levels and, in the case of DNA-histone complexes, were associated with RBC and platelet transfusion. However, NET burden did not significantly differ between patients who experienced thrombosis and those free of thrombosis. This may be attributable to the relatively modest increases in NETs and the presence of stronger causative factors underlying thrombophilia in patients with CHD. Plasma lactic acid was a common covariate for makers of NETosis and ADAMTS-13 in this study, and was associated with postoperative thrombosis in univariate analysis. This suggests that poor tissue perfusion or postoperative metabolic stress are linked to hematologic changes and clinical outcomes in patients undergoing pediatric cardiac surgery.
Multivariate analysis also revealed that cryoprecipiate transfusion volume was associated with postoperative thrombosis. Cryoprecipitate is principally administered to correct hypofibrinogenemia following cardiac surgery. Although the transfusion volume of cryoprecipitate and the postoperative levels of VWF did not show a significant association, cryoprecipitate nonetheless represents a source of exogenous VWF administered to a patient population with high levels of endogenous VWF release and relatively attenuated ADAMTS-13 activity in the postoperative period. Other prothromboic factors enriched in cryoprecipitate (e.g. FVIII [49, 50] and platelet membrane microparticles [51] ) may contribute etiologically to this association.
The limitations of this study include the small sample size and corresponding low total number of thrombotic events, which results in wide estimates of effect. Furthermore, only a few factors that may contribute to thrombosis were evaluated. However, no prior studies have evaluated ADAMTS-13, VWF and NETs for their relationship with thrombophilia in this patient population. Prior efforts to identify predictive markers of thrombosis have focused on specific CHD subpopulations (e.g. singleventricle neonates [52, 53] ).
Thrombophilia in neonates and infants with complex heart malformations has a multifactorial basis. Intraoperative exposure to extreme physiologic conditions of lactic acidosis, hypothermia and extracorporeal circulation results in significant derangements to hemostasis, necessitating large transfusion volumes. This occurs in a patient population often harboring pre-existing hematologic irregularities and risk factors for thrombosis. As this study shows, one abnormality that appears to be consistent across a diversity of CHD patients is a functional imbalance between VWF and ADAMTS-13 in the perioperative period. Given the ability of ADAMTS-13 to degrade VWF into smaller, less thrombotic forms, these findings suggest that addressing the relatively low activity levels of ADAMTS-13 could have clinical benefit. Assessing perioperative recombinant ADAMTS-13 supplementation as a novel thromboprophylaxis strategy may have merit in this patient population.
